Cargando…
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy
Autores principales: | Wadsley, Jon, Ainsworth, Gemma, Coulson, Amy Beth, Garcez, Kate, Moss, Laura, Newbold, Kate, Farnell, Kate, Swain, Jayne, Howard, Helen, Beasley, Matthew, Weaver, Andrew, Wood, Katie, Marshall, Jennifer, Griffin, Matthew, Pascoe, Abigail, Du, Yong, Taprogge, Jan, Flux, Glenn, Brown, Sarah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516223/ https://www.ncbi.nlm.nih.gov/pubmed/37565288 http://dx.doi.org/10.1089/thy.2022.0707 |
Ejemplares similares
-
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial
por: Brown, Sarah R., et al.
Publicado: (2019) -
The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer
por: Taprogge, Jan, et al.
Publicado: (2023) -
Recommendations for Multicentre Clinical Trials Involving Dosimetry for Molecular Radiotherapy
por: Taprogge, J., et al.
Publicado: (2021) -
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial
por: Dehbi, Hakim-Moulay, et al.
Publicado: (2019) -
Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project
por: Taprogge, Jan, et al.
Publicado: (2023)